newsfilter
← Latest News
Business Wire·

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

EQ

Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA,